Study on the effect of Phaltrikadi Churna in controlling cholesterol levels.

Clinical Evaluation of Phaltrikadi Churna in the Management of Medoroga (Dyslipidemia) - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/111068

Enrollment

Registered

2026-05-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients with primary dyslipidemia (not secondary to other diseases). Patients who give written informed consent to participate. Patients having one or more than one levels among criteria according to National Cholesterol Education Program ATP III classification: Patients having serum cholesterol level 200mg/dL 239mg/dL. Patients having serum LDL level 130mg/dL 159mg/dL. Patients having serum HDL level less than 40 mg/dL Patients having serum triglyceride level 150mg/dL 199mg/dL.

Exclusion criteria

Exclusion criteria: Patient with a history of chronic or excessive alcohol consumption. Individuals who are pregnant or currently lactating. Patients with any lipid Profile value exceeding the upper limits defined in the inclusion criteria. Patients who are on lipid lowering agent. Patients with secondary dyslipidemia (due to hypothyroidism, nephrotic syndrome, diabetes mellitus,etc.)

Design outcomes

Primary

Measure	Time frame
To assess the change in lipid profile parameters, including total cholesterol, triglycerides, LDL, and HDL levels, after administration of Phaltrikadi Churna in patients with dyslipidemia, indicating its efficacy in managing abnormal lipid levels.Timepoint: Assessment will be done at baseline, then at 2nd week, 4th week, 6th week and after the completion of treatment at 8th week. Follow up will be done at an interval of 30 days after the completion of trial.	—

Measure

Time frame

To assess the change in lipid profile parameters, including total cholesterol, triglycerides, LDL, and HDL levels, after administration of Phaltrikadi Churna in patients with dyslipidemia, indicating its efficacy in managing abnormal lipid levels.Timepoint: Assessment will be done at baseline, then at 2nd week, 4th week, 6th week and after the completion of treatment at 8th week. Follow up will be done at an interval of 30 days after the completion of trial.

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactAbhishek Thakur

Quadra Institute of Ayurveda and Hospital Roorkee

drrajnikant83@gmail.com8054114530

Outcome results